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We report a case of hematopoietic stem cell trans-
plantation (HSCT) from an HLA-identical brother
with no signs of hepatic graft-versus-host disease
(GVHD), hepatic rejection, or hepatic sinusoidal ob-
struction syndrome (SOS) in a patient with severe
aplastic anemia (SAA) who had previously undergone
living-related liver transplantation (LRLT) from an
HLA-haploidentical sister for fulminant hepatitis. An
18-year-old female was transferred to our institution
with hepatic encephalopathy. On admission, her labo-
ratory data were as follows: total bilirubin, 204 mmol/
L; prothrombin time-INR, 2.26; white blood cell
count, 5.7  109/L; hemoglobin, 109 g/L; platelet
count, 90  109/L. Markers for viral hepatitis were
negative. Three days after admission, the patient un-
derwent an auxiliary partial orthotopic LRLT using
a left liver graft from her ABO-matched, HLA-haploi-
dentical sister. Histological examination demonstrated
hepatic necrosis, but the patient exhibited no signs ofTable I. HSCT in patients with aplastic anemia post-liver transplan
Patient and Reference
Liver Transplant
Donor/Source HSCT Source HSCT Do
6.5-year-old male1 (Cadaveric) Marrow HLA-matched
29-year-old male2 (Cadaveric) Marrow HLA-matched
2.5-year-old male3 (Cadaveric) Marrow HLA-matched

















MTX indicates methotrexate; PSL, prednisolone; HSCT, hematopoietic stem ce
no data; Cy, cyclophosphamide; TLI, total lymphoid irradiation; SOS, sinusoida
*Serologic mismatch.chronic hepatic disease. Tacrolimus and methylpred-
nisolone were administered for rejection prophylaxis.
Progressive pancytopenia developed after trans-
plantation (absolute neutrophil count [ANC], 0.8 
109/L; hemoglobin, 58 g/L; platelet count, 37  109/
L on day 7). Bone marrow biopsy revealed hypoplastic
marrow with cellularity\10%. A diagnosis of hepati-
tis-associated SAA was assigned. Administration of
horse antithymocyte globulin (ATG) or rabbit ATG
together with cyclosporine A (CsA) and granulocyte
colony-stimulating factor (G-CSF) resulted in only
transient hematologic recovery (ANC . 1.0  109/L).
Evaluation of liver function by technetium-99m galac-
tosyl serum albumin (GSA) scintigraphy revealed nor-
mal liver function reserve (LHL15 5 0.935 [normal,
. 0.91]) with accumulation predominately in the right
lobe, suggesting native liver regeneration.
Given the patient’s status, we decided to perform
HSCT using bone marrow from her HLA-matched
brother. The conditioning regimen comprised cyclo-
phosphamide (Cy), 50 mg/kg/day for 5 days, and 7.5
Gy of total lymphoid irradiation (TLI). For HSCT,
the patient received 2.8  108 marrow mononuclear
cells/kg. Immunosuppression after transplantation
consisted of 3 doses of methotrexate (MTX; 10 mg/
kg on day 1 and 7 mg/kg on days 3 and 6), continuous
infusion of CsA (with a target blood level of 450 to 550
ng/mL), and methylprednisolone 2 mg/day. She
achieved an ANC. 0.5 109/L on day 14 after trans-
plantation. Full donor chimerism was confirmed by
XY fluorescein in situ hybridization (FISH) on day
28. The posttransplantation course was uneventful,








sister CsA/MTX/PSL Cy/ATG - - 2 years
brother CyA/PSL CY/TLI Skin
grade I
- 1 year
sister CsA/MTX/PSL Cy/ATG - - 3 years
brother FK506/MTX/PSL Cy/ATG - - 1 year
sister CyA/MTX Cy/TLI - + 9 months
ND ATG/CsA/
PSL/G-CSF
ND - 3 years
rother CyA/MTX/PSL Cy/TLI - - 6 months
ll transplantation; FK506, tacrolimus; ATG, antithymocyte globulin; ND,
l obstruction syndrome; CsA, cyclosporine; EFS, event-free survival.
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lent health and free from any signs of chronic GVHD
or liver dysfunction on the basis of symptoms, labora-
tory data, computed tomography, and abdominal ul-
trasonography, on a daily regimen of CsA 200 mg
and methylprednisolone 2 mg.
To the best of our knowledge, 6 cases of HSCT for
SAA after liver transplantation have been reported pre-
viously (Table 1) [1-6]. Significantly, only 1 of these
patients underwent allogeneic HSCT for SAA; this pa-
tient had received a serologically one-locus-mis-
matched (in the graft-versus-host direction) liver
transplant from his father and a serologically identical
stem cell transplant from his sister [5]. The most sig-
nificant conclusion that can be drawn from the present
case is that allogeneic HSCT for a recipient of HLA-
haploidentical LRLT can be performed safely, at least
in conjunction with sufficient immunosuppression
therapy. We also report here the possible usefulness
of GSA scintigraphy before HSCT as a functional
evaluation of the recipient’s own liver, considering
that severe GVHD can impair the function of an
HLA-haploidentical liver graft.REFERENCES
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